School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong; Department of Pharmacy, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
Department of Public Health, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia; Deakin Health Economics, Institute for Health Transformation, Deakin University, Geelong, Victoria.
J Glob Antimicrob Resist. 2022 Dec;31:175-184. doi: 10.1016/j.jgar.2022.09.001. Epub 2022 Sep 8.
Tuberculosis (TB) is the leading infectious cause of mortality worldwide. Despite the development of different antituberculosis drugs, managing resistant mycobacteria is still challenging. The discovery of novel drugs and new methods of targeted drug delivery have the potential to improve treatment outcomes, lower the duration of treatment, and reduce adverse events. Following bedaquiline and delamanid, pretomanid is the third medicine approved as part of a novel drug regimen for treating drug-resistant TB. It is a promising drug that has the capacity to shape TB treatment and achieve the End TB strategy set by the World Health Organization. The effectiveness of pretomanid has been reported in different observational and clinical studies. However, long-term safety data in humans are not yet available and the pretomanid-based regimen is recommended under an operational research framework that prohibits its wider and programmatic use. Further research is needed before pretomanid can be celebrated as a promising candidate for the treatment of different categories of TB and specific patients. This review covers the update on pretomanid development and its clinical roles in treating Mycobacterium tuberculosis.
结核病（TB）是全球主要的传染病死因。尽管已经开发出不同的抗结核药物，但管理耐药分枝杆菌仍然具有挑战性。新型药物的发现和靶向药物输送的新方法有可能改善治疗效果、缩短治疗时间并减少不良反应。在贝达喹啉和德拉马尼之后，普托马尼是作为治疗耐药结核病新药物方案的一部分获得批准的第三种药物。它是一种很有前途的药物，有能力改变结核病治疗方法并实现世界卫生组织制定的终结结核病战略。普托马尼在不同的观察性和临床研究中都有疗效报告。然而，目前还没有人类长期安全性数据，而且基于普托马尼的方案是在一个禁止更广泛和计划性使用的操作研究框架下推荐的。在将普托马尼作为治疗不同类型结核病和特定患者的有前途的候选药物而受到庆祝之前，还需要进一步的研究。这篇综述涵盖了普托马尼开发的最新进展及其在治疗结核分枝杆菌中的临床作用。
